A detailed history of Cross Staff Investments Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Cross Staff Investments Inc holds 7,163 shares of BMY stock, worth $413,161. This represents 0.3% of its overall portfolio holdings.

Number of Shares
7,163
Previous 7,155 0.11%
Holding current value
$413,161
Previous $297,000 24.58%
% of portfolio
0.3%
Previous 0.25%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$39.66 - $51.75 $317 - $414
8 Added 0.11%
7,163 $370,000
Q2 2024

Aug 06, 2024

BUY
$40.25 - $52.99 $362 - $476
9 Added 0.13%
7,155 $297,000
Q1 2024

May 01, 2024

BUY
$47.98 - $54.4 $383 - $435
8 Added 0.11%
7,146 $387,000
Q4 2023

Feb 02, 2024

BUY
$48.48 - $57.85 $339 - $404
7 Added 0.1%
7,138 $366,000
Q3 2023

Oct 17, 2023

BUY
$57.89 - $64.73 $347 - $388
6 Added 0.08%
7,131 $413,000
Q2 2023

Aug 01, 2023

BUY
$63.71 - $70.74 $318 - $353
5 Added 0.07%
7,125 $455,000
Q1 2023

Apr 25, 2023

SELL
$65.71 - $74.53 $2,956 - $3,353
-45 Reduced 0.63%
7,120 $493,000
Q4 2022

Jan 30, 2023

BUY
$68.48 - $81.09 $342 - $405
5 Added 0.07%
7,165 $515,000
Q3 2022

Oct 21, 2022

BUY
$0.13 - $76.84 $0 - $307
4 Added 0.06%
7,160 $509,000
Q2 2022

Oct 21, 2022

BUY
$72.62 - $79.98 $7,697 - $8,477
106 Added 1.5%
7,156 $551,000
Q2 2022

Jul 29, 2022

SELL
$72.62 - $79.98 $7,334 - $8,077
-101 Reduced 1.41%
7,050 $551,000
Q1 2022

Apr 19, 2022

BUY
$61.48 - $73.72 $368 - $442
6 Added 0.08%
7,151 $522,000
Q4 2021

Feb 07, 2022

BUY
$53.63 - $62.52 $383,186 - $446,705
7,145 New
7,145 $445,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Cross Staff Investments Inc Portfolio

Follow Cross Staff Investments Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cross Staff Investments Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cross Staff Investments Inc with notifications on news.